Sarepta療法 SRPT 深 滬
等待開盤 03-26 09:30:00 美东时间
23.77
+6.160
+34.98%
華盛通- 最 高23.85
- 今 開19.76
- 成交量 1704.34万股
- 最 低 19.67
- 昨 收 17.61
- 總市值 24.96亿
- 52周最高 64.80
- 市盈率 靜 --
- 換手率 16.23%
- 52周最低 10.415
- 委 比 -94.99%
- 總股本 1.05亿
- 歷史最高 181.83
- 量 比 6.78
- 振 幅 23.74%
- 歷史最低 0.433
- 每 手 1
- 風險率 14.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Sarepta Therapeutics Stock Exploding Today?
Sarepta stock jumps after siRNA data show protein reduction, while analysts remain split on outlook and valuation.
03-25 23:17
Sarepta gains on data for muscular dystrophy therapies
Sarepta Therapeutics (SRPT) added ~25% in the morning hours on Wednesday after the company posted initial data from Phase 1/2 trials for its experimental drugs targeted at two rare forms of muscular d...
03-25 21:49
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
BUZZ-U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 25 (Reuters) - Wall Street's main indexes were set to open higher on W
03-25 21:29
Sarepta Reports Early siRNA Trial Results With Strong Muscle Targeting And Favorable Safety Profile
In early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1Company to host investor call on March 25, 2026, at 8:30 a.m.
03-25 20:07
新浪财经ESG：Sarepta Therapeutics MSCI（明晟）ESG评级调降至B
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:29
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Sarepta stock slips after FDA update and mixed trial results, as investors weigh approval hopes against weak data signals.
03-19 23:51
Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $37 Price Target
Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $37 price target.
03-19 22:38
Sarepta Begins Enrolling Non-Ambulatory Duchenne Patients In ENDEAVOR Cohort Testing Sirolimus Safety Protocol With ELEVIDYS
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study- The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver
03-16 20:35
Sarepta begins ENDEAVOR Cohort 8 trial of ELEVIDYS with sirolimus in 25 non-ambulant Duchenne patients
Sarepta begins ENDEAVOR Cohort 8 trial of ELEVIDYS with sirolimus in 25 non-ambulant Duchenne patients Sarepta reported that screening and enrollment have begun in Cohort 8 of the open-label Phase 1b ENDEAVOR study evaluating ELEVIDYS in non-ambulant males with Duchenne muscular dystrophy. The cohor
03-16 20:33
